Results from the analysis indicated that patients who received R1 and R2 surgical resection experienced a better overall survival (OS) vs those who received chemotherapy alone. Patients who underwent R1/R2 resection and neoadjuvant therapy experienced the best median OS of 19.75 months (95% CI, 17.91-22.28) vs 16.92 months with up-front surgery (95% CI, 16.03-17.81) and 9.04 months with chemotherapy alone (95% CI, 8.87-9.26). Read more . . .
Surgical resection demonstrated a notable survival benefit, particularly in combination with neoadjuvant therapy, in patients with aggressive margin-positive pancreatic cancer, according to data from an analysis published in the Journal of the American College of Surgeons.